▶ 調査レポート

世界の樹状細胞ワクチン市場(~2028年):非ターゲット、ターゲット

• 英文タイトル:Global Dendritic Cell Vaccine Market Insights, Forecast to 2028

Global Dendritic Cell Vaccine Market Insights, Forecast to 2028「世界の樹状細胞ワクチン市場(~2028年):非ターゲット、ターゲット」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2Q12-18979
• 出版社/出版日:QYResearch / 2022年12月
• レポート形態:英文、PDF、119ページ
• 納品方法:Eメール(納期:3営業日)
• 産業分類:医薬品&医療
• 販売価格(消費税別)
  Single User¥725,200 (USD4,900)▷ お問い合わせ
  Enterprise License¥1,450,400 (USD9,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、樹状細胞ワクチンのグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。
樹状細胞ワクチンのアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。
樹状細胞ワクチンの中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。
樹状細胞ワクチンのヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。

生産面において、本レポートは2017年から2022年までの樹状細胞ワクチンの生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の樹状細胞ワクチンの売上および2028年までの予測に焦点を当てています。

樹状細胞ワクチンのグローバル主要企業には、3M、Activarti、Argos Therapeutics、Batavia Bioservices、Bellicum Pharmaceuticals、Creagene、DanDrit Biotech、DCPrime、Sanpower Corporation (Dendreon Corporation)、Elios Therapeutics、ImmunoCellular Therapeutics、Immunicum、Kiromic、Medigene、Merck & Co.、Northwest Biotherapeutics、Glaxo Smith Kline、Tella Incorporation、Vaxil BioTherapeuticsなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

樹状細胞ワクチン市場は、タイプとアプリケーションによって区分されます。世界の樹状細胞ワクチン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。

【タイプ別セグメント】
非ターゲット、ターゲット

【アプリケーション別セグメント】
新型コロナウイルス感染症、癌、その他

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- 樹状細胞ワクチン製品概要
- タイプ別市場(非ターゲット、ターゲット)
- アプリケーション別市場(新型コロナウイルス感染症、癌、その他)
- 調査の目的
・エグゼクティブサマリー
- 世界の樹状細胞ワクチン販売量予測2017-2028
- 世界の樹状細胞ワクチン売上予測2017-2028
- 樹状細胞ワクチンの地域別販売量
- 樹状細胞ワクチンの地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別樹状細胞ワクチン販売量
- 主要メーカー別樹状細胞ワクチン売上
- 主要メーカー別樹状細胞ワクチン価格
- 競争状況の分析
- 企業M&A動向
・タイプ別市場規模(非ターゲット、ターゲット)
- 樹状細胞ワクチンのタイプ別販売量
- 樹状細胞ワクチンのタイプ別売上
- 樹状細胞ワクチンのタイプ別価格
・アプリケーション別市場規模(新型コロナウイルス感染症、癌、その他)
- 樹状細胞ワクチンのアプリケーション別販売量
- 樹状細胞ワクチンのアプリケーション別売上
- 樹状細胞ワクチンのアプリケーション別価格
・北米市場
- 北米の樹状細胞ワクチン市場規模(タイプ別、アプリケーション別)
- 主要国別の樹状細胞ワクチン市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパの樹状細胞ワクチン市場規模(タイプ別、アプリケーション別)
- 主要国別の樹状細胞ワクチン市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋の樹状細胞ワクチン市場規模(タイプ別、アプリケーション別)
- 主要国別の樹状細胞ワクチン市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米の樹状細胞ワクチン市場規模(タイプ別、アプリケーション別)
- 主要国別の樹状細胞ワクチン市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカの樹状細胞ワクチン市場規模(タイプ別、アプリケーション別)
- 主要国別の樹状細胞ワクチン市場規模(トルコ、サウジアラビア)
・企業情報
3M、Activarti、Argos Therapeutics、Batavia Bioservices、Bellicum Pharmaceuticals、Creagene、DanDrit Biotech、DCPrime、Sanpower Corporation (Dendreon Corporation)、Elios Therapeutics、ImmunoCellular Therapeutics、Immunicum、Kiromic、Medigene、Merck & Co.、Northwest Biotherapeutics、Glaxo Smith Kline、Tella Incorporation、Vaxil BioTherapeutics
・産業チェーン及び販売チャネル分析
- 樹状細胞ワクチンの産業チェーン分析
- 樹状細胞ワクチンの原材料
- 樹状細胞ワクチンの生産プロセス
- 樹状細胞ワクチンの販売及びマーケティング
- 樹状細胞ワクチンの主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 樹状細胞ワクチンの産業動向
- 樹状細胞ワクチンのマーケットドライバー
- 樹状細胞ワクチンの課題
- 樹状細胞ワクチンの阻害要因
・主な調査結果

Dendritic cells (DCs) have several characteristics that make them an ideal vehicle for tumor vaccines, and with the first US FDA-approved DC-based vaccine in use for the treatment of prostate cancer, this technology has become a promising new therapeutic option.
Market Analysis and Insights: Global Dendritic Cell Vaccine Market
Due to the COVID-19 pandemic, the global Dendritic Cell Vaccine market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Non-Targeted accounting for % of the Dendritic Cell Vaccine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Covid-19 segment is altered to an % CAGR throughout this forecast period.
China Dendritic Cell Vaccine market size is valued at US$ million in 2021, while the US and Europe Dendritic Cell Vaccine are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Dendritic Cell Vaccine landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Dendritic Cell Vaccine include 3M, Activarti, Argos Therapeutics, Batavia Bioservices, Bellicum Pharmaceuticals, Creagene, DanDrit Biotech, DCPrime and Sanpower Corporation (Dendreon Corporation), etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Dendritic Cell Vaccine Scope and Segment
Dendritic Cell Vaccine market is segmented By Type and By Application. Players, stakeholders, and other participants in the global Dendritic Cell Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast By Type and By Application for the period 2017-2028.
Segment By Type
Non-Targeted
Target
Segment By Application
Covid-19
Cancer
Others
By Company
3M
Activarti
Argos Therapeutics
Batavia Bioservices
Bellicum Pharmaceuticals
Creagene
DanDrit Biotech
DCPrime
Sanpower Corporation (Dendreon Corporation)
Elios Therapeutics
ImmunoCellular Therapeutics
Immunicum
Kiromic
Medigene
Merck & Co.
Northwest Biotherapeutics
Glaxo Smith Kline
Tella Incorporation
Vaxil BioTherapeutics
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

レポート目次

1 Study Coverage
1.1 Dendritic Cell Vaccine Product Introduction
1.2 Market By Type
1.2.1 Global Dendritic Cell Vaccine Market Size Growth Rate By Type, 2017 VS 2021 VS 2028
1.2.2 Non-Targeted
1.2.3 Target
1.3 Market By Application
1.3.1 Global Dendritic Cell Vaccine Market Size Growth Rate By Application, 2017 VS 2021 VS 2028
1.3.2 Covid-19
1.3.3 Cancer
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Dendritic Cell Vaccine Sales Estimates and Forecasts 2017-2028
2.2 Global Dendritic Cell Vaccine Revenue Estimates and Forecasts 2017-2028
2.3 Global Dendritic Cell Vaccine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Dendritic Cell Vaccine Sales by Region
2.4.1 Global Dendritic Cell Vaccine Sales by Region (2017-2022)
2.4.2 Global Sales Dendritic Cell Vaccine by Region (2023-2028)
2.5 Global Dendritic Cell Vaccine Revenue by Region
2.5.1 Global Dendritic Cell Vaccine Revenue by Region (2017-2022)
2.5.2 Global Dendritic Cell Vaccine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Dendritic Cell Vaccine Sales by Manufacturers
3.1.1 Global Top Dendritic Cell Vaccine Manufacturers by Sales (2017-2022)
3.1.2 Global Dendritic Cell Vaccine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Dendritic Cell Vaccine in 2021
3.2 Global Dendritic Cell Vaccine Revenue by Manufacturers
3.2.1 Global Dendritic Cell Vaccine Revenue by Manufacturers (2017-2022)
3.2.2 Global Dendritic Cell Vaccine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Dendritic Cell Vaccine Revenue in 2021
3.3 Global Dendritic Cell Vaccine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Dendritic Cell Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Dendritic Cell Vaccine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size By Type
4.1 Global Dendritic Cell Vaccine Sales By Type
4.1.1 Global Dendritic Cell Vaccine Historical Sales By Type (2017-2022)
4.1.2 Global Dendritic Cell Vaccine Forecasted Sales By Type (2023-2028)
4.1.3 Global Dendritic Cell Vaccine Sales Market Share By Type (2017-2028)
4.2 Global Dendritic Cell Vaccine Revenue By Type
4.2.1 Global Dendritic Cell Vaccine Historical Revenue By Type (2017-2022)
4.2.2 Global Dendritic Cell Vaccine Forecasted Revenue By Type (2023-2028)
4.2.3 Global Dendritic Cell Vaccine Revenue Market Share By Type (2017-2028)
4.3 Global Dendritic Cell Vaccine Price By Type
4.3.1 Global Dendritic Cell Vaccine Price By Type (2017-2022)
4.3.2 Global Dendritic Cell Vaccine Price Forecast By Type (2023-2028)
5 Market Size By Application
5.1 Global Dendritic Cell Vaccine Sales By Application
5.1.1 Global Dendritic Cell Vaccine Historical Sales By Application (2017-2022)
5.1.2 Global Dendritic Cell Vaccine Forecasted Sales By Application (2023-2028)
5.1.3 Global Dendritic Cell Vaccine Sales Market Share By Application (2017-2028)
5.2 Global Dendritic Cell Vaccine Revenue By Application
5.2.1 Global Dendritic Cell Vaccine Historical Revenue By Application (2017-2022)
5.2.2 Global Dendritic Cell Vaccine Forecasted Revenue By Application (2023-2028)
5.2.3 Global Dendritic Cell Vaccine Revenue Market Share By Application (2017-2028)
5.3 Global Dendritic Cell Vaccine Price By Application
5.3.1 Global Dendritic Cell Vaccine Price By Application (2017-2022)
5.3.2 Global Dendritic Cell Vaccine Price Forecast By Application (2023-2028)
6 North America
6.1 North America Dendritic Cell Vaccine Market Size By Type
6.1.1 North America Dendritic Cell Vaccine Sales By Type (2017-2028)
6.1.2 North America Dendritic Cell Vaccine Revenue By Type (2017-2028)
6.2 North America Dendritic Cell Vaccine Market Size By Application
6.2.1 North America Dendritic Cell Vaccine Sales By Application (2017-2028)
6.2.2 North America Dendritic Cell Vaccine Revenue By Application (2017-2028)
6.3 North America Dendritic Cell Vaccine Market Size by Country
6.3.1 North America Dendritic Cell Vaccine Sales by Country (2017-2028)
6.3.2 North America Dendritic Cell Vaccine Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Dendritic Cell Vaccine Market Size By Type
7.1.1 Europe Dendritic Cell Vaccine Sales By Type (2017-2028)
7.1.2 Europe Dendritic Cell Vaccine Revenue By Type (2017-2028)
7.2 Europe Dendritic Cell Vaccine Market Size By Application
7.2.1 Europe Dendritic Cell Vaccine Sales By Application (2017-2028)
7.2.2 Europe Dendritic Cell Vaccine Revenue By Application (2017-2028)
7.3 Europe Dendritic Cell Vaccine Market Size by Country
7.3.1 Europe Dendritic Cell Vaccine Sales by Country (2017-2028)
7.3.2 Europe Dendritic Cell Vaccine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Dendritic Cell Vaccine Market Size By Type
8.1.1 Asia Pacific Dendritic Cell Vaccine Sales By Type (2017-2028)
8.1.2 Asia Pacific Dendritic Cell Vaccine Revenue By Type (2017-2028)
8.2 Asia Pacific Dendritic Cell Vaccine Market Size By Application
8.2.1 Asia Pacific Dendritic Cell Vaccine Sales By Application (2017-2028)
8.2.2 Asia Pacific Dendritic Cell Vaccine Revenue By Application (2017-2028)
8.3 Asia Pacific Dendritic Cell Vaccine Market Size by Region
8.3.1 Asia Pacific Dendritic Cell Vaccine Sales by Region (2017-2028)
8.3.2 Asia Pacific Dendritic Cell Vaccine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Dendritic Cell Vaccine Market Size By Type
9.1.1 Latin America Dendritic Cell Vaccine Sales By Type (2017-2028)
9.1.2 Latin America Dendritic Cell Vaccine Revenue By Type (2017-2028)
9.2 Latin America Dendritic Cell Vaccine Market Size By Application
9.2.1 Latin America Dendritic Cell Vaccine Sales By Application (2017-2028)
9.2.2 Latin America Dendritic Cell Vaccine Revenue By Application (2017-2028)
9.3 Latin America Dendritic Cell Vaccine Market Size by Country
9.3.1 Latin America Dendritic Cell Vaccine Sales by Country (2017-2028)
9.3.2 Latin America Dendritic Cell Vaccine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Dendritic Cell Vaccine Market Size By Type
10.1.1 Middle East and Africa Dendritic Cell Vaccine Sales By Type (2017-2028)
10.1.2 Middle East and Africa Dendritic Cell Vaccine Revenue By Type (2017-2028)
10.2 Middle East and Africa Dendritic Cell Vaccine Market Size By Application
10.2.1 Middle East and Africa Dendritic Cell Vaccine Sales By Application (2017-2028)
10.2.2 Middle East and Africa Dendritic Cell Vaccine Revenue By Application (2017-2028)
10.3 Middle East and Africa Dendritic Cell Vaccine Market Size by Country
10.3.1 Middle East and Africa Dendritic Cell Vaccine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Dendritic Cell Vaccine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 3M
11.1.1 3M Corporation Information
11.1.2 3M Overview
11.1.3 3M Dendritic Cell Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 3M Dendritic Cell Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 3M Recent Developments
11.2 Activarti
11.2.1 Activarti Corporation Information
11.2.2 Activarti Overview
11.2.3 Activarti Dendritic Cell Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Activarti Dendritic Cell Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Activarti Recent Developments
11.3 Argos Therapeutics
11.3.1 Argos Therapeutics Corporation Information
11.3.2 Argos Therapeutics Overview
11.3.3 Argos Therapeutics Dendritic Cell Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Argos Therapeutics Dendritic Cell Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Argos Therapeutics Recent Developments
11.4 Batavia Bioservices
11.4.1 Batavia Bioservices Corporation Information
11.4.2 Batavia Bioservices Overview
11.4.3 Batavia Bioservices Dendritic Cell Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Batavia Bioservices Dendritic Cell Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Batavia Bioservices Recent Developments
11.5 Bellicum Pharmaceuticals
11.5.1 Bellicum Pharmaceuticals Corporation Information
11.5.2 Bellicum Pharmaceuticals Overview
11.5.3 Bellicum Pharmaceuticals Dendritic Cell Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Bellicum Pharmaceuticals Dendritic Cell Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Bellicum Pharmaceuticals Recent Developments
11.6 Creagene
11.6.1 Creagene Corporation Information
11.6.2 Creagene Overview
11.6.3 Creagene Dendritic Cell Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Creagene Dendritic Cell Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Creagene Recent Developments
11.7 DanDrit Biotech
11.7.1 DanDrit Biotech Corporation Information
11.7.2 DanDrit Biotech Overview
11.7.3 DanDrit Biotech Dendritic Cell Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 DanDrit Biotech Dendritic Cell Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 DanDrit Biotech Recent Developments
11.8 DCPrime
11.8.1 DCPrime Corporation Information
11.8.2 DCPrime Overview
11.8.3 DCPrime Dendritic Cell Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 DCPrime Dendritic Cell Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 DCPrime Recent Developments
11.9 Sanpower Corporation (Dendreon Corporation)
11.9.1 Sanpower Corporation (Dendreon Corporation) Corporation Information
11.9.2 Sanpower Corporation (Dendreon Corporation) Overview
11.9.3 Sanpower Corporation (Dendreon Corporation) Dendritic Cell Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Sanpower Corporation (Dendreon Corporation) Dendritic Cell Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Sanpower Corporation (Dendreon Corporation) Recent Developments
11.10 Elios Therapeutics
11.10.1 Elios Therapeutics Corporation Information
11.10.2 Elios Therapeutics Overview
11.10.3 Elios Therapeutics Dendritic Cell Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Elios Therapeutics Dendritic Cell Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Elios Therapeutics Recent Developments
11.11 ImmunoCellular Therapeutics
11.11.1 ImmunoCellular Therapeutics Corporation Information
11.11.2 ImmunoCellular Therapeutics Overview
11.11.3 ImmunoCellular Therapeutics Dendritic Cell Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 ImmunoCellular Therapeutics Dendritic Cell Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 ImmunoCellular Therapeutics Recent Developments
11.12 Immunicum
11.12.1 Immunicum Corporation Information
11.12.2 Immunicum Overview
11.12.3 Immunicum Dendritic Cell Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Immunicum Dendritic Cell Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Immunicum Recent Developments
11.13 Kiromic
11.13.1 Kiromic Corporation Information
11.13.2 Kiromic Overview
11.13.3 Kiromic Dendritic Cell Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Kiromic Dendritic Cell Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Kiromic Recent Developments
11.14 Medigene
11.14.1 Medigene Corporation Information
11.14.2 Medigene Overview
11.14.3 Medigene Dendritic Cell Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Medigene Dendritic Cell Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Medigene Recent Developments
11.15 Merck & Co.
11.15.1 Merck & Co. Corporation Information
11.15.2 Merck & Co. Overview
11.15.3 Merck & Co. Dendritic Cell Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Merck & Co. Dendritic Cell Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Merck & Co. Recent Developments
11.16 Northwest Biotherapeutics
11.16.1 Northwest Biotherapeutics Corporation Information
11.16.2 Northwest Biotherapeutics Overview
11.16.3 Northwest Biotherapeutics Dendritic Cell Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Northwest Biotherapeutics Dendritic Cell Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Northwest Biotherapeutics Recent Developments
11.17 Glaxo Smith Kline
11.17.1 Glaxo Smith Kline Corporation Information
11.17.2 Glaxo Smith Kline Overview
11.17.3 Glaxo Smith Kline Dendritic Cell Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 Glaxo Smith Kline Dendritic Cell Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Glaxo Smith Kline Recent Developments
11.18 Tella Incorporation
11.18.1 Tella Incorporation Corporation Information
11.18.2 Tella Incorporation Overview
11.18.3 Tella Incorporation Dendritic Cell Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.18.4 Tella Incorporation Dendritic Cell Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Tella Incorporation Recent Developments
11.19 Vaxil BioTherapeutics
11.19.1 Vaxil BioTherapeutics Corporation Information
11.19.2 Vaxil BioTherapeutics Overview
11.19.3 Vaxil BioTherapeutics Dendritic Cell Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.19.4 Vaxil BioTherapeutics Dendritic Cell Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 Vaxil BioTherapeutics Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Dendritic Cell Vaccine Industry Chain Analysis
12.2 Dendritic Cell Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Dendritic Cell Vaccine Production Mode & Process
12.4 Dendritic Cell Vaccine Sales and Marketing
12.4.1 Dendritic Cell Vaccine Sales Channels
12.4.2 Dendritic Cell Vaccine Distributors
12.5 Dendritic Cell Vaccine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Dendritic Cell Vaccine Industry Trends
13.2 Dendritic Cell Vaccine Market Drivers
13.3 Dendritic Cell Vaccine Market Challenges
13.4 Dendritic Cell Vaccine Market Restraints
14 Key Findings in The Global Dendritic Cell Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer